PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2020; 78(08): 461-467
DOI: 10.1590/0004-282X20200027
Article

Effects of statin therapy on outcomes of ischemic stroke: a real-world experience in Brazil

Efeitos da terapia com estatinas nos desfechos do acidente vascular cerebral isquêmico: uma experiência de mundo real no Brasil
Bruno Kusznir VITTURI 
1   Santa Casa de São Paulo, School of Medical Sciences, Department of Neurology, São Paulo SP, Brazil.
,
Rubens José GAGLIARDI 
1   Santa Casa de São Paulo, School of Medical Sciences, Department of Neurology, São Paulo SP, Brazil.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

ABSTRACT

Background: Statin therapy has become one of the most important advances in stroke secondary prevention. Objective: To provide evidence from real-world data for evaluating detailed associations between secondary prevention of stroke and statin use in Brazil. Methods: We conducted a prospective cohort study including consecutive patients diagnosed with an ischemic stroke. Subjects were classified into non-statin, simvastatin 20 mg, simvastatin 40 mg, and high-potency statin groups. We also registered the onset of statin therapy, previous use of statins, the adherence to medication, and if there was discontinuation of the therapy. After two years, the functional outcome, stroke recurrence, major cardiovascular events, and mortality were assessed. Results: Among the 513 patients included in our cohort, there were 96 (18.7%) patients without statins, 169 (32.9%) with simvastatin 20 mg, 202 (39.3%) with simvastatin 40 mg, and 46 (9.0%) with high-potency statins. Patients without statins were at increased risk of stroke recurrence and worse functional outcomes. Concerning etiology, evidence of beneficial use of statins was observed in cases of large-artery atherosclerosis, small-vessel occlusion, and stroke of undetermined cause. Those who presented poor adherence to statins or discontinuation of the treatment had worse prognosis after stroke whereas the early onset of statins use was associated with better outcomes. Patients with simvastatin 40 mg and high-potency statins presented the best functional recovery throughout the follow-up. Conclusions: Statins play an important role in the treatment of ischemic stroke, preventing stroke recurrence and cardiovascular events, and improving functional performance.

RESUMO

Introdução: A terapia com estatinas tornou-se um dos avanços mais importantes na prevenção secundária do acidente vascular cerebral (AVC). Objetivo: Fornecer evidências de dados do mundo real para avaliar associações detalhadas entre a prevenção secundária do AVC e o uso de estatinas no Brasil. Métodos: Realizamos um estudo de coorte prospectivo, incluindo pacientes consecutivos com diagnóstico de AVC isquêmico. Os indivíduos foram classificados em grupos sem estatinas, sinvastatina 20 mg, sinvastatina 40 mg e estatina de alta potência. Também registramos o início da terapêutica com estatinas, o uso prévio de estatinas, a adesão à medicação e se houve descontinuação da terapia. Após dois anos, foram avaliados o resultado funcional, a recorrência do AVC, os principais eventos cardiovasculares e a mortalidade. Resultados: Entre os 513 pacientes incluídos em nossa coorte, havia 96 (18,7%) pacientes sem estatinas, 169 (32,9%) com sinvastatina 20 mg, 202 (39,3%) com sinvastatina 40 mg e 46 (9,0%) com estatinas de alta potência. Pacientes sem estatinas apresentaram maior risco de recorrência de AVC e piores resultados funcionais. Em relação à etiologia, foram observadas evidências do benefício das estatinas nos casos de aterosclerose de grandes artérias, oclusão de pequenos vasos e AVC de causa indeterminada. Aqueles com baixa adesão às estatinas ou que interromperam o uso tiveram pior prognóstico após o AVC, enquanto o início precoce do uso de estatinas foi associado a melhores resultados. Pacientes com sinvastatina 40 mg e estatinas de alta potência apresentaram melhor recuperação funcional ao longo do período de acompanhamento. Conclusões: As estatinas desempenham um importante papel no tratamento do AVC isquêmico, prevenindo sua recorrência e eventos cardiovasculares e melhorando o desempenho funcional.

Keywords:

Statin - Ischemic stroke - Outcomes - Prevention

Palavras-chave:

Estatinas - Acidente vascular cerebral isquêmico - Desfechos - Prevenção


Publikationsverlauf

Eingereicht: 03. Februar 2020

Angenommen: 17. Februar 2020

Artikel online veröffentlicht:
13. Juni 2023

© 2020. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017 Nov;16(11):877-97. https//doi.org/10.1016/S1474-4422(17)30299-5
  • 2 Ouriques Martins SC, Sacks C, Hacke W, Brainin M, de Assis Figueiredo F, Marques Pontes-Neto O, et al. Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurol. 2019 Jul;18(7):674-83. https//doi.org/10.1016/S1474-4422(19)30068-7
  • 3 Feigin VL, Norrving B, George MG, Foltz JL, Roth GA, Mensah GA. Prevention of stroke: A strategic global imperative. Nat Rev Neurol. 2016 Sep;12(9):501-12. https//doi.org/10.1038/nrneurol.2016.107
  • 4 Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009 May;8(5):453-63. https//doi.org/10.1016/S1474-4422(09)70058-4
  • 5 Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Stroke. 2012 Feb;43(2):e18-e19. https//doi.org/10.1161/STROKEAHA.111.638940
  • 6 Ní Chróinín D, Asplund K, Åsberg S, Callaly E, Cuadrado-Godia E, Díez-Tejedor E, et al. Statin therapy and outcome after ischemic stroke: Systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013 Feb;44(2):448-56. https//doi.org/10.1161/STROKEAHA.112.668277
  • 7 Katkade VB, Sanders KN, Zou KH. Real world data: An opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018 Jul;11:295-304. https//doi.org/10.2147/JMDH.S160029
  • 8 Castilla-Guerra L, Fernandez-Moreno M del C, Leon-Jimenez D, Rico-Corral MA. Statins in Ischemic stroke prevention: what have we learned in the post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade? Curr Treat Options Neurol. 2019 Apr;21(5):22. https//doi.org/10.1007/s11940-019-0563-4
  • 9 Davis SM, Donnan GA. Secondary prevention after ischemic stroke or transient ischemic attack. N Engl J Med. 2012 May;366:1914-22. https//doi.org/10.1056/NEJMcp1107281
  • 10 Smith M, Lee N, Haney E, Carson S, Helfand M. Drug class review HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin. Portland (OR): Oregon Health & Science University; 2009.
  • 11 Vitturi BK, Pellegrinelli A, Valerio BCO. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study. Acta Neurol Belg. 2020 Feb;120(1):83-9. https//doi.org/10.1007/s13760-019-01209-0
  • 12 Vitturi BK, Gagliardi RJ. Use of CHADS2 and CHA2DS2-VASc scores to predict prognosis after stroke. Rev Neurol (Paris). 2019 Jun;176(1-2):85-91. https//doi.org/10.1016/j.neurol.2019.05.001
  • 13 Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012 Jan;43(1):147-54. https//doi.org/10.1161/STROKEAHA.111.627729
  • 14 Amarenco P, Moskowitz MA. The dynamics of statins: From event prevention to neuroprotection. Stroke. 2006 Feb;37(2):294-6. https//doi.org/10.1161/01.STR.0000201856.90105.ab
  • 15 Yang Z, Edwards D, Massou E, Saunders CL, Brayne C, Mant J. Statin use and high-dose statin use after ischemic stroke in the UK: A retrospective cohort study. Clin Epidemiol. 2019 Jun;11:495-508. https//doi.org/10.2147/CLEP.S201983
  • 16 Scheitz JF, Seiffge DJ, Tütüncü S, Gensicke H, Audebert HJ, Bonati LH, et al. Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke. 2014 Feb;45(2):509-14. https//doi.org/10.1161/STROKEAHA.113.002751
  • 17 Canavero I, Cavallini A, Perrone P, Magoni M, Sacchi L, Quaglini S, et al. Clinical factors associated with statins prescription in acute ischemic stroke patients: Findings from the Lombardia Stroke Registry. BMC Neurol. 2014 Mar;14:53. https//doi.org/10.1186/1471-2377-14-53
  • 18 The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug;355(6):549-5. https//doi.org/10.1056/NEJMoa061894
  • 19 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. https//doi.org/ 10.1161/STR.20200027202000270158.
  • 20 Furie KL. High-dose statins should only be used in atherosclerotic strokes. Stroke. 2012 Jul;43(7):1994-5. https//doi.org/10.1161/STROKEAHA.111.633339
  • 21 Tramacere I, Boncoraglio GB, Banzi R, Del Giovane C, Kwag KH, Squizzato A, et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: A systematic review and network meta-analysis. BMC Med. 2019 Mar;17(1):67. https//doi.org/10.1186/s12916-019-1298-5
  • 22 Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008 Jun;70(24 Pt 2):2364-70. https://doi.org/10.1212/01.wnl.0000296277.63350.77
  • 23 Amarenco P, Tonkin AM. Statins for stroke prevention: Disappointment and hope. Circulation. 2004 Jun;109(23 Suppl 1):III44-9. https//doi.org/10.1161/01.cir.0000131518.25959.8f
  • 24 He L, Xu R, Wang J, Zhang L, Zhao W, Dong W. Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke. BMC Neurol. 2019 Oct;19(1):240. https//doi.org/10.1186/s12883-019-1463-7
  • 25 Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke. 2008 Jun;39(6):1779-85. https//doi.org/10.1161/STROKEAHA.107.501700
  • 26 Kim J, Lee HS, Nam CM, Heo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. 2017 Oct;48(10):2723-30. https//doi.org/10.1161/STROKEAHA.117.018140
  • 27 Chung PW, Yoon BW, Lee YB, Shin BS, Kim HY, Park JH, et al. Medication Adherence of Statin Users after Acute Ischemic Stroke. Eur Neurol. 2018 Nov;80(1-2):106-14. https//doi.org/10.1159/000493530
  • 28 Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology. 2007 Aug;69(9):904-10. https//doi.org/10.1212/01.wnl.0000269789.09277.47
  • 29 Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007 Oct;38(10):2652-7. https//doi.org/10.1161/STROKEAHA.107.487017
  • 30 Vitturi BK, Gagliardi RJ. The role of statins in cardioembolic stroke. J Clin Neurosci. 2019 Dec;72:174-9. https//doi.org/ 10.1016/j.jocn.2019.12.028